Please assess the completion status of the following clinical trial:

Trial Title: Colesevelam as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Type 2 diabetes mellitus~* Inadequate glycemic control on a stable dose (at least 2 months prior to screening) of pioglitazone at 30 or 45 mg/day, with or without one or two other oral antidiabetic medications \[metformin or a sulfonylurea, or dipeptidyl peptidase (DPP-IV) inhibitor\]~* Hemoglobin A1c (HbA1c) \>= 7.5% and =\< 9.5% at screening~* Fasting plasma glucose =\<240 mg/dL at randomization (Week 0/Day 1).~* Male or female \>= 18 years of age.~* Women of childbearing potential must be using an adequate method of contraception as detailed per-protocol~* Fasting C-peptide level \>0.5 ng/mL at screening~* Clinically stable in regards to medical conditions other than type 2 diabetes~* Concomitant medications are at stable doses for at least 30 days prior to enrollment, and are not anticipated to need adjustment during the study period~Exclusion Criteria:~* History of Type 1 diabetes and/or history of ketoacidosis~* History of bowel obstruction~* History of hypertriglyceridemia-induced pancreatitis~* Fasting serum triglyceride concentration \>500 mg/dL~* History of dysphagia, swallowing disorders, gastroparesis, other gastrointestinal motility disorders, major gastrointestinal surgery~* History of insulin use \>= 2 weeks duration during the previous 3 months or a total of \>2 months insulin therapy at any time prior to screening~* Treatment with bile acid sequestrants, including colesevelam within 3 months prior to screening~* Female subject who is pregnant or breastfeeding~* History of unstable angina, myocardial infarction, cerebrovascular accident, transient ischemic attack, or any revascularization within 6 months prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Colesevelam (Type: EXPERIMENTAL): Participants receive six colesevelam tablets (3.8 grams/day) in addition to pioglitazone-based therapy (30 mg or 45 mg)
- Placebo (Type: PLACEBO_COMPARATOR): Participants receive six placebo tablets in addition to pioglitazone-based therapy (30 mg or 45 mg)

Based on this trial design, predict the completion outcome and termination type (if applicable).